The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Some good buying coming through. Several buys of 5k+
I think the JV with Paragraf looks key and this has the potential to have a marked difference in performance. Otherwise now if I'm an FD/CFO and looking to make a significant investment in this area and there's no clear differentiator in performance then I would be looking at aftersales and who's going to be around to honour the warranty on the product if needed. Verditek have a number of risks associated with them but the market is massive and the lightweight/flexibility aspect of the product is quite cool, throw in a real boost to productivity then you really have potential. I'm in for more at 8p, worth another 6 months of a gamble for me.
Unless these are professional portfolio level executives and did this type of engagement regularly, then yes, perhaps this would have a chance of succeeding if they have enough clout and C-level contacts in their pockets. If on the other hand these people are not at this level and in fact looking for a full time paying role to cover their monthly bills, then I would not hold out so much hope for them producing results quick enough. I guess it depends on how you see it. You get what you pay for generally.
I think today's placing is actually pretty positive, and gives VDTK some strategic flexibility.
1) It funds w/c and enables them to possibly meet anticipated orders in the pipeline
2) Eliminates funding concerns
3) The size of the fund raise suggests to me that it isn't purely about funding w/c and could help accelerate capacity expansion at both Lainate and possibly in a strategic mkt (Australia?) This would enable VDTK to cut costs and accelerate demand
4) If an institutional investor or two are part of the fund raise this would be a significant vote of confidence in VDTK's management and strategy
5) The last fund raise in May was followed by a 500% increase in the SP from 3p to 18p. Yes we need the orders to come through in Nov/Dec and a positive update from Paragraf, but if they come through then there doesn't imo seem much downside in the SP. As the old adage goes, A Bird in the hand is worth two in the bush.
Disappointing here of the placement news. I’m in with a average of 13p here, so have quite a way to go.
Who is able to buy at 8p placing price? Is this to private investors, existing shareholders of what?
SnipVW. I disagree that commission only sales people are not motivated to sell the product. If I was commission only I would be more motivated to sell than if I was base plus commission. Providing the commission structure is good it is highly motivating for a good sales person.
disappointing but predictable. There was no way in hell that they had generated enough income. They need to hire full time sales pro's. People who are working commission only are not fully motivated, they are not 100% focused on pushing this product. If a good proportion of this raise does not go to funding proper staff the company will wither away.
Verditek plc ("Verditek" or "Company"), the international clean technology company that develops, manufactures and sells certified lightweight solar panels, is pleased to announce that the Company is carrying out a placing to raise approximately up to £3.5 million, before expenses, via the issue of up to 43,750,000 new Ordinary Shares ("Placing Shares") at the issue price of 8 pence per share ("Issue Price") ("Placing").
Key Highlights:
· Proposed fundraising of approximately up to £3.5 million, before expenses, at a price of 8 pence per share by way of a Placing.
· Net proceeds of the Placing will be used principally to provide working capital for the Company (to fund the cash lag between purchase of raw materials and sales receipts as production ramps up) and to strengthen the balance sheet.